Hansoh Pharmaceutical Group stock
Price history
−13.92% over the period1 year: from $39.38 (November 17, 2025) to $33.90 (November 16, 2026), −13.92%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $33.90 |
| October 30, 2026 | $32.36 |
| September 30, 2026 | $35.30 |
| August 31, 2026 | $35.34 |
| July 31, 2026 | $32.18 |
| June 30, 2026 | $29.62 |
| May 29, 2026 | $31.44 |
| April 30, 2026 | $37.10 |
| March 31, 2026 | $35.48 |
| February 27, 2026 | $34.96 |
| January 30, 2026 | $38.60 |
| December 31, 2025 | $36.08 |
| November 28, 2025 | $40.22 |
| November 17, 2025 | $39.38 |
At a glance
The company
Researches, develops, produces and sells pharmaceutical products for oncology, anti-infection, central nervous system and metabolic diseases in China
Latest results
Quarter to June 30, 2026 · EPS ¥0.70
TickerLandia's take on Hansoh Pharmaceutical Group
- Cheaper than similar companies: trailing 12-month P/E 28 vs 36 (−21%) in a group of 11.
- Strong point: Financial strength (92/100 in its group). Weak point: Dividend (41/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−23.34% from the 52-week high
Analysts · 23 analysts
Average target$48.38+42.72% vs. price
Buy 23 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: Hansoh Pharmaceutical Group
Compared with similar companies: very high financial strength and very high profitability.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricehigh71
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 28.4 56 EV/EBITDA 27.9 79 Forward P/E 25.6 63 Price/book 4.70 68 Price/sales 13.1 91 Profitabilityvery high87
How much it earns on revenue and capital.
Metric Value Position in group ROA 9.1% 73 ROE 19.4% 78 Operating margin 37.3% 91 Gross margin 90.5% 96 Net margin 42.0% 99 Earnings stabilityaverage54
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.8% 46 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthhigh71
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +33.20% 77 Average revenue growth (3 years) +17.00% 88 Revenue growth (year over year) +11.70% 49 Financial strengthvery high92
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −5.46 99 Interest coverage 1,708.2 99 Debt/equitycounts in reverse: lower means more financial strength 0.11 78 Current ratio 4.88 91 Dividendaverage41
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 6 years 26 Dividend yield 1.4% 44 Payout ratio 40.1% 53 Market momentumaverage53
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +9.22% 64 Relative strength (6 months) +6.27% 59 1-year return −10.60% 30 Distance from 200-day average +1.07% 58 Riskhigh63
How much the price swings.
Metric Value Position in group Beta (1 year) 0.89 60 Volatility (60 days) 55.1% 76 Maximum drawdown (12 months) 34.1% 51
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Hansoh Pharmaceutical Group is cheaper than similar companies
Hansoh Pharmaceutical Group's P/E (trailing 12 months): 28.4, −21% against the median of a group of 11 similar companies (35.9).
Compared with 11 similar companies
| Metric | Hansoh Pharmaceutical Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 28.4 | Middle | |
| Forward P/E | 25.6 | Middle | |
| Operating margin | 37.3% | High | |
| ROE | 19.4% | Middle | |
| Debt/equity | 0.11 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Hansoh Pharmaceutical Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥8.3B
Latest quarter · Q2 2026
Net income
¥4.26B
Latest quarter · Q2 2026
Quarterly net margin
51.3%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $208.68B
- P/E
- 28.4
- EPS
- $1.21
- Volume
- 6.3M
- Daily trading
- €46.32M
- Dividend yield
- 1.43%
- Last ex-dividend on September 22, 2026
How Hansoh Pharmaceutical Group is changing
All resultsRevenue grew 11.6% a year on average over the last 5 years
Operating margin rose from 27.8% to 35.9%
Profits turn into cash: free cash flow equal to 98% of net income
Returns
Hansoh Pharmaceutical Group returns with dividends
$1,000 invested in Hansoh Pharmaceutical Group 5 years ago, on November 16, 2021, would be worth $1,938 today with dividends reinvested: +93.76% in total, +14.15% per year. On price alone it would be $1,817 (+81.67%).
| Period | Hansoh Pharmaceutical Group | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | +6.81% | −1.79% | $1,068 |
| 6 months | −3.58% | −8.96% | $964 |
| Year to date | −6.04% | −7.32% | $940 |
| 1 year | −12.71% | −9.97% | $873 |
| 3 years | +145.06% | +33.20% | $2,451 |
| 5 years | +93.76% | −7.62% | $1,938 |
Over the last 6 months it has done better than 36% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Hang Seng: price only. Calculate your investment
The chart in detail
Hansoh Pharmaceutical Group: technical analysis
Hansoh Pharmaceutical Group shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 25.4% below its all-time closing high ($45.45, January 22, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 51
- Between 30 and 70
- vs 200-session average
- −0.36%
Support and resistance
Price areas where Hansoh Pharmaceutical Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$37.33+10.12%2 touches, last on September 4, 2026
- Resistance$36.27+6.99%2 touches, last on September 23, 2026
- Resistance$35.16+3.72%7 touches, last on November 5, 2026
- Last price$33.90
- Support$33.61−0.87%3 touches, last on September 29, 2026
- Support$30.76−9.26%6 touches, last on November 3, 2026
- Support$28.10−17.11%2 touches, last on June 26, 2026
Volatility and risk
Over the last year it has moved roughly in line with the Hang Seng.
- Beta (1 year) vs Hang Seng
- 0.91
- Volatility (60 sessions, annualised)
- 55.0%
- Largest fall in the last year
- −34.13%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Hansoh Pharmaceutical Group: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for Hansoh Pharmaceutical Group has been November: +6.35% on average, positive in 5 years out of 7. The weakest has been September: −3.18% on average, positive in 4 years out of 8.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.12% | +6.98% | 5 of 7 |
| February | −1.27% | −3.39% | 3 of 7 |
| March | +2.34% | −2.77% | 3 of 7 |
| April | +3.40% | +4.57% | 4 of 7 |
| May | −0.52% | +0.89% | 4 of 7 |
| June | +4.15% | +1.62% | 5 of 7 |
| July | +0.66% | +1.45% | 4 of 8 |
| August | +2.89% | +6.16% | 6 of 8 |
| September | −3.18% | 0.00% | 4 of 8 |
| October | −0.99% | −5.32% | 1 of 8 |
| November | +6.35% | +7.33% | 5 of 7 |
| December | +1.55% | 0.00% | 3 of 7 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Hansoh Pharmaceutical Group and its competitors
Based in Shanghai and in existence since its founding in 1995, Hansoh Pharmaceutical Group Company Limited develops, makes and sells medicines for the Chinese market, with a portfolio spanning anti-infection drugs, central nervous system treatments, oncology, metabolic diseases and autoimmune conditions. Its product names include Ameile, Hansoh Xinfu, Pulaile, Xintai, Hengmu and XINYUE.
- Headquarters
- Shanghai, China
- Employees
- 9,643
- Founded
- 1995
- Chief executive
- Huijuan Zhong
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group3692 | $26.6B | 37.3% | 28.4 | −3.58% |
| Divi's LaboratoriesDIVISLAB | $32.23B | 34.0% | 90.6 | +63.89% |
| Torrent PharmaceuticalsTORNTPHARM | $18.85B | 22.2% | 78.9 | +6.48% |
| PharmaEssentia6446 | $16.42B | 40.3% | 59.4 | +73.91% |
| Shionogi &4507 | $16.87B | 18.6% | 11.2 | +5.13% |
| Jiangsu Hengrui Pharmaceuticals600276 | $47.82B | 27.4% | 35.9 | −11.06% |
Same industry or related industries, similar size. Compare Hansoh Pharmaceutical Group with its competitors · Full profile
More on Hansoh Pharmaceutical Group
- Hansoh Pharmaceutical Group revenue and financials
- Hansoh Pharmaceutical Group dividend and valuation
- Hansoh Pharmaceutical Group stock return
- Hansoh Pharmaceutical Group employees, headquarters and business
